Read Between These Lines As Eli Lilly, Hot IPO And More Face Key TestInvestors Business Daily • 08/03/26
Will Mounjaro & Zepbound Drive Lilly's Q2 Results: Buy, Sell or Hold?Zacks Investment Research • 08/03/26
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancerPRNewsWire • 08/03/26
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 08/02/26
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key LevelsInvestors Business Daily • 07/31/26
Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 07/31/26
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your PatientsThe Motley Fool • 07/29/26
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.The Motley Fool • 07/29/26
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 EarningsZacks Investment Research • 07/28/26